Harmony Biosciences (HRMY) Set to Release Earnings on Wednesday

Harmony Biosciences (NASDAQ:HRMY) is anticipated to issue its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Harmony Biosciences to announce earnings of $1.10 per share and revenue of $274.04 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Tuesday, August 4th. The company reported $1.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.96 by $0.32. The firm had revenue of $261.28 million for the quarter, compared to analysts’ expectations of $250.77 million. During the same quarter last year, the company posted $0.92 EPS. The firm’s revenue was up 30.3% on a year-over-year basis. On average, analysts expect Harmony Biosciences to post $3.79 EPS for the current fiscal year and $4.06 EPS for the next fiscal year.

Harmony Biosciences Price Performance

Shares of NASDAQ:HRMY opened at $37.95 on Wednesday. The stock has a 50 day moving average price of $39.78 and a 200-day moving average price of $34.72. Harmony Biosciences has a 52-week low of $25.90 and a 52-week high of $43.49.

Insider Activity at Harmony Biosciences

In other news, insider Kumar Budur sold 35,852 shares of the business’s stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $43.05, for a total transaction of $1,543,428.60. Following the transaction, the insider owned 13,115 shares of the company’s stock, valued at approximately $564,600.75. The trade was a 73.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last three months, insiders sold 72,406 shares of company stock valued at $3,108,520. 11.00% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research firms have recently commented on HRMY. Zacks Research raised Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 15th. Mizuho boosted their target price on shares of Harmony Biosciences from $50.00 to $51.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Needham & Company LLC reiterated a “buy” rating and issued a $50.00 price objective on shares of Harmony Biosciences in a research note on Monday, October 19th. Truist Financial raised their target price on Harmony Biosciences from $29.00 to $34.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Finally, Weiss Ratings raised shares of Harmony Biosciences from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, October 12th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $48.20.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial-stage biopharmaceutical company focused on developing and providing therapies for patients with rare neurological disorders. The company’s activities center on conditions involving sleep-wake regulation and other central nervous system disorders where treatment options may be limited.

Harmony’s principal product is WAKIX (pitolisant), an oral, non-scheduled treatment that acts as a histamine-3 receptor antagonist/inverse agonist. In the United States, WAKIX is approved for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy and for excessive daytime sleepiness in pediatric patients aged 6 and older with narcolepsy.